الفهرس 
Polycystic Ovary SyndromeOnly 14 pages are availabe for public view
 |  | from | 245 |  |  |
| | | from | 245 | | |
Abstract
PCOS is the most common metabolic abnormality in young women today, occurring in 10% of female patients of reproductive age. Women with polycystic ovary syndrome (PCOS) constitute the largest group of women at risk for the devel¬opment of cardiovascular disease (CVD) and diabetes.
The aetiology of PCOS is complex and multifactorial, and the pathogenesis of PCOS is not fully understood. One possible mechanism for metabolic abnormalities in PCOS involves adipocytokines, which play a key role in the pathogenesis of a number of metabolic syndromes besides obesity. They also have an impact on immune Function and may modulate cardiovascular morbidity and mortality.
Adipose tissue has been established as a major endocrine organ, through the release of peptides such as adiponectin, resistin, and leptin, it is involved in the pathogenesis of several metabolic disorders, through the study of adipocyte-specific glucose trans¬porter 4 (Glut 4) knockout mice, retinol-binding protein 4 (RBP4) has been identified as another adipocyte-derived molecule that contributes to obesity and type 2 DM in humans.
Retinol binding protein 4 (RBP4) is a 21-kDa single polypeptide chain protein best known for being the principal physiological carrier of retinol, the parent vitamin A molecule, in blood. RBP4 helps vertebrates adapt to fluctuations in dietary vitamin A intake by allowing the delivery of retinol from tissue storage sites to target tissues.
In humans, several studies have found a correlation between serum RBP4 levels and the magnitude of insulin resistance in subjects with obesity, impaired glucose tolerance or type 2 diabetes. It is suggested that RBP is a central mediator of obesity-induced insulin resistance in mice and humans.
In addition, elevated serum RBP levels have been associated with cardiovascular risk factors and metabolic syndromes, including high blood pressure, lipid profile and inflammatory markers.
The study included 90 subjects divided into 4 groups:
Group (I): 30 lean patients with the diagnosis of PCOS.
Group (II): 30 obese patients with the diagnosis of PCOS.
Group (III): 15 lean control women.
Group (IIII): 15 obese control women.
The results were statically analyzed and we observed the following:
Regarding serum RBP4 between PCOS group and control group: The level of Retinol binding protein 4 was significantly higher in PCOS group than control group with P value < 0.001. And as regards serum fasting insulin level and HOMA-IR in both PCOS subjects and healthy women: There was highly statistical significant difference between the two groups as regards serum fasting insulin with P value < 0.001, while there was a statistical significant difference between the two groups as regards HOMA-IR with P value < 0.05.
Regarding RBP4 in subjects presenting with polycystic ovary syndrome:
There was a high significant statistical positive correlation between RBP4 and weight (r=0.425), BMI (r=0.428), waist circumference (r=0.373), W/H ratio (r=0.427), serum fasting insulin (r=0.370), HOMA-IR (r=0.374), triglyceride (r=0.447) and LDL- cholesterol (r=0.372) with P value <0.01, and there was a high significant statistical negative correlation between RBP4 and HDL- cholesterol (r=-0.351) with P value <0.01. There was a positive significant statistical correlation between retinol binding protein 4 and post prandial plasma glucose (r=0.303) and HBA1c (r=0.281) with P value <0.05. There was a positive but non significant statistical correlation between RBP4 and age (r=0.125), height(r=0.188), hip circumference (r=0.097), systolic blood pressure (r=0.197), diastolic blood pressure (r=0.015), fasting plasma glucose (r=0.196), free testosterone (r=0.010) and serum uric acid (r=115) with P value >0.05, and there was a negative but non significant statistical correlation between RBP4 and age of menarche (r=-0.63) and LH hormone (r=-0.061) with P value >0.05.